Research Projects

Helix

    Initial Research Foci 1: HIV-Resistant Anti-HIV CAR T Cells

    IRF1 Leaders & Industry Partners:
    Lawrence Corey, MD, Fred Hutchinson Cancer Research Center • Seattle, Washington
    David Rawlings, MD, Seattle Children’s Hospital • Seattle, Washington
    Thor Wagner, MD, Seattle Children’s Hospital • Seattle, Washington
    Juno Therapeutics, Seattle, Washington
    Gilead Sciences, Foster City, California
    Sangamo BioSciences, Richmond, California

     

    Initial Research Foci 2: eCD4-Ig based Therapy for HIV Cure

    IRF2 Leaders & Industry Partners:
    Michael Farzan, PhD, The Scripps Research Institute Florida • Jupiter, Florida
    Emmune, Inc., Jupiter, Florida
    Gilead Sciences, Foster City, California

     

    Initial Research Foci 3: Genetic Protection of T Cells after Therapeutic Vaccination

    IRF3 Leaders & Industry Partners:
    James Mullins, PhD
    , University of Washington • Seattle, Washington
    Deborah Fuller, PhD, University of Washington • Seattle, Washington
    Hans-Peter Kiem, MD, PhD, Fred Hutchinson Cancer Research Center • Seattle, Washington
    Sangamo BioSciences, Richmond, California
    Gilead Sciences, Foster City, California